Published in J Med Chem on October 14, 2016
Invasion of Host Cells and Tissues by Uropathogenic Bacteria. Microbiol Spectr (2016) 0.75
Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease. Expert Opin Drug Discov (2017) 0.75
Targeting microbial biofilms: current and prospective therapeutic strategies. Nat Rev Microbiol (2017) 0.75
Intracellular bacterial biofilm-like pods in urinary tract infections. Science (2003) 7.10
Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov (2010) 4.23
Where will new antibiotics come from? Nat Rev Microbiol (2003) 3.99
Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon (2003) 3.54
Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med (2007) 3.54
FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the Enterobacteriaceae. Proc Natl Acad Sci U S A (1995) 3.51
Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection. Mol Microbiol (2002) 3.26
Interaction of mannose-containing oligosaccharides with the fimbrial lectin of Escherichia coli. Biochem Biophys Res Commun (1982) 2.19
Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med (2011) 2.16
Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis (1996) 2.15
A murine model of urinary tract infection. Nat Protoc (2009) 2.15
From carbohydrate leads to glycomimetic drugs. Nat Rev Drug Discov (2009) 2.13
Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding. J Cell Sci (2001) 2.13
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. Antimicrob Agents Chemother (2010) 2.05
Integrin-mediated host cell invasion by type 1-piliated uropathogenic Escherichia coli. PLoS Pathog (2007) 2.01
Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol Microbiol (2005) 1.90
Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog (2010) 1.88
Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob Agents Chemother (2006) 1.76
Type 1 pili-mediated adherence of Escherichia coli strain LF82 isolated from Crohn's disease is involved in bacterial invasion of intestinal epithelial cells. Mol Microbiol (2001) 1.73
Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am (2013) 1.67
Carbohydrate-binding sites of the mannose-specific fimbrial lectins of enterobacteria. Infect Immun (1984) 1.63
Anti-adhesion therapy of bacterial diseases: prospects and problems. FEMS Immunol Med Microbiol (2003) 1.57
A brief history of the antibiotic era: lessons learned and challenges for the future. Front Microbiol (2010) 1.56
Urinary tract infection in adults: research priorities and strategies. Int J Antimicrob Agents (2001) 1.51
B cell infiltration and lymphonodular hyperplasia in bladder submucosa of patients with persistent bacteriuria and recurrent urinary tract infections. J Urol (2011) 1.50
Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Escherichia coli to yeast and intestinal epithelial cells. Infect Immun (1987) 1.41
Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J Med Chem (2010) 1.40
Bacterial pathogenesis: exploiting cellular adherence. Curr Opin Cell Biol (2003) 1.27
Cyclodextrins in delivery systems: Applications. J Pharm Bioallied Sci (2010) 1.20
FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem (2010) 1.14
Mannosylated G(0) dendrimers with nanomolar affinities to Escherichia coli FimH. ChemMedChem (2007) 1.10
Evaluation of the carbohydrate recognition domain of the bacterial adhesin FimH: Design, synthesis and binding properties of mannoside ligands. Org Biomol Chem (2006) 1.09
Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides. J Med Chem (2012) 1.05
Targeting virulence for antimicrobial chemotherapy. Curr Opin Pharmacol (2003) 1.03
Bacterial adhesion to animal tissues: protein determinants for recognition of extracellular matrix components. Cell Microbiol (2012) 1.02
Role of inflammation in bladder function and interstitial cystitis. Ther Adv Urol (2011) 1.02
Recurrence of urinary tract infections in adult patients with community-acquired pyelonephritis caused by E. coli: a 1-year follow-up. Scand J Infect Dis (2000) 1.01
Design, synthesis and biological evaluation of mannosyl triazoles as FimH antagonists. Bioorg Med Chem (2011) 0.98
Synthetic multimeric heptyl mannosides as potent antiadhesives of uropathogenic Escherichia coli. ChemMedChem (2009) 0.95
Antiadhesion therapy for urinary tract infections--a balanced PK/PD profile proved to be key for success. J Med Chem (2012) 0.95
Inhibition of Cyclooxygenase-2 Prevents Chronic and Recurrent Cystitis. EBioMedicine (2014) 0.93
Combining glycomimetic and multivalent strategies toward designing potent bacterial lectin inhibitors. Chemistry (2011) 0.93
Structure, folding and stability of FimA, the main structural subunit of type 1 pili from uropathogenic Escherichia coli strains. J Mol Biol (2011) 0.92
Inhibition of the type 1 fimbriae-mediated adhesion of Escherichia coli to erythrocytes by multiantennary alpha-mannosyl clusters: the effect of multivalency. Glycoconj J (1998) 0.92
Glycomimetics versus multivalent glycoconjugates for the design of high affinity lectin ligands. Chem Rev (2014) 0.92
Anti-adhesion methods as novel therapeutics for bacterial infections. Expert Rev Anti Infect Ther (2012) 0.91
Who will develop new antibacterial agents? Philos Trans R Soc Lond B Biol Sci (2014) 0.90
Thiazolylaminomannosides as potent antiadhesives of type 1 piliated Escherichia coli isolated from Crohn's disease patients. J Med Chem (2013) 0.90
Uropathogenic Escherichia coli superinfection enhances the severity of mouse bladder infection. PLoS Pathog (2015) 0.90
Escherichia coli in chronic inflammatory bowel diseases: An update on adherent invasive Escherichia coli pathogenicity. World J Gastrointest Pathophysiol (2014) 0.88
Glycomimetic drugs--a new source of therapeutic opportunities. Discov Med (2009) 0.87
The tyrosine gate of the bacterial lectin FimH: a conformational analysis by NMR spectroscopy and X-ray crystallography. Chembiochem (2015) 0.87
Follicular cystitis in girls with untreated asymptomatic or covert bacteriuria. J Urol (1990) 0.86
FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile. J Med Chem (2015) 0.85
Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease. Expert Opin Ther Pat (2016) 0.84
Discovery of two classes of potent glycomimetic inhibitors of Pseudomonas aeruginosa LecB with distinct binding modes. ACS Chem Biol (2013) 0.84
FimH antagonists: structure-activity and structure-property relationships for biphenyl α-D-mannopyranosides. ChemMedChem (2012) 0.81
DMSO Represses Inflammatory Cytokine Production from Human Blood Cells and Reduces Autoimmune Arthritis. PLoS One (2016) 0.81
Structure of a glycomimetic ligand in the carbohydrate recognition domain of C-type lectin DC-SIGN. Structural requirements for selectivity and ligand design. J Am Chem Soc (2013) 0.80
Heptyl α-D-mannosides grafted on a β-cyclodextrin core to interfere with Escherichia coli adhesion: an in vivo multivalent effect. Chemistry (2013) 0.79
Glycoconjugates and Glycomimetics as Microbial Anti-Adhesives. Trends Biotechnol (2016) 0.79
Structures of C-mannosylated anti-adhesives bound to the type 1 fimbrial FimH adhesin. IUCrJ (2016) 0.78
Hydrogen-bonding cooperativity: using an intramolecular hydrogen bond to design a carbohydrate derivative with a cooperative hydrogen-bond donor centre. Chemistry (2004) 0.77
Unique DC-SIGN clustering activity of a small glycomimetic: A lesson for ligand design. ACS Chem Biol (2014) 0.77
Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI. ChemMedChem (2016) 0.77
FimH Antagonists: Phosphate Prodrugs Improve Oral Bioavailability. J Med Chem (2016) 0.76
Second generation of thiazolylmannosides, FimH antagonists for E. coli-induced Crohn's disease. Org Biomol Chem (2016) 0.76
The Antiadhesive Strategy in Crohn's Disease: Orally Active Mannosides to Decolonize Pathogenic Escherichia coli from the Gut. Chembiochem (2016) 0.76
Synthesis of novel polyhydroxylated pyrrolidine-triazole/-isoxazole hybrid molecules. Org Biomol Chem (2015) 0.76
Preparation of 1-C-glycosyl aldehydes by reductive hydrolysis. Carbohydr Res (2011) 0.75
Improved preparations of some per-O-acetylated aldohexopyranosyl cyanides. Carbohydr Res (1986) 0.75
Role of Escherichia coli curli operons in directing amyloid fiber formation. Science (2002) 5.58
Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci U S A (2008) 4.45
Fiber formation across the bacterial outer membrane by the chaperone/usher pathway. Cell (2008) 2.69
Chaperone priming of pilus subunits facilitates a topological transition that drives fiber formation. Cell (2002) 2.54
Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation. Nat Chem Biol (2009) 2.52
Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med (2011) 2.16
Quantitative metabolomics reveals an epigenetic blueprint for iron acquisition in uropathogenic Escherichia coli. PLoS Pathog (2009) 1.83
Antibody responses and protection from pyelonephritis following vaccination with purified Escherichia coli PapDG protein. J Urol (2004) 1.82
Home testing to detect human immunodeficiency virus: boon or bane? J Clin Microbiol (2006) 1.79
A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131. J Infect Dis (2013) 1.76
Crystal structure of the FimD usher bound to its cognate FimC-FimH substrate. Nature (2011) 1.67
The extracytoplasmic adaptor protein CpxP is degraded with substrate by DegP. Proc Natl Acad Sci U S A (2005) 1.58
Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose binding. Proc Natl Acad Sci U S A (2009) 1.56
Management of blood shortages in a tertiary care academic medical center: the Yale-New Haven Hospital frozen blood reserve. Transfusion (2008) 1.49
QseC-mediated dephosphorylation of QseB is required for expression of genes associated with virulence in uropathogenic Escherichia coli. Mol Microbiol (2009) 1.47
Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J Med Chem (2010) 1.40
The Legionella pneumophila PilT homologue DotB exhibits ATPase activity that is critical for intracellular growth. J Bacteriol (2004) 1.39
LeuX tRNA-dependent and -independent mechanisms of Escherichia coli pathogenesis in acute cystitis. Mol Microbiol (2007) 1.37
Utilization of an intracellular bacterial community pathway in Klebsiella pneumoniae urinary tract infection and the effects of FimK on type 1 pilus expression. Infect Immun (2008) 1.36
Periplasmic peptidyl prolyl cis-trans isomerases are not essential for viability, but SurA is required for pilus biogenesis in Escherichia coli. J Bacteriol (2005) 1.35
Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. Genet Med (2012) 1.34
A central metabolic circuit controlled by QseC in pathogenic Escherichia coli. Mol Microbiol (2011) 1.26
Mechanism for sortase localization and the role of sortase localization in efficient pilus assembly in Enterococcus faecalis. J Bacteriol (2009) 1.23
Design and synthesis of C-2 substituted thiazolo and dihydrothiazolo ring-fused 2-pyridones: pilicides with increased antivirulence activity. J Med Chem (2010) 1.22
A novel endogenous inhibitor of the secreted streptococcal NAD-glycohydrolase. PLoS Pathog (2005) 1.20
Catalysis of protein folding by chaperones in pathogenic bacteria. Proc Natl Acad Sci U S A (2004) 1.18
Common themes and variations in serine protease autotransporters. Trends Microbiol (2008) 1.17
Escherichia coli biofilms have an organized and complex extracellular matrix structure. MBio (2013) 1.17
Molecular variations in Klebsiella pneumoniae and Escherichia coli FimH affect function and pathogenesis in the urinary tract. Infect Immun (2008) 1.07
Nonaromatic amidine derivatives as acylation catalysts. Org Lett (2007) 1.07
Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides. J Med Chem (2012) 1.05
Chaperone-subunit-usher interactions required for donor strand exchange during bacterial pilus assembly. J Bacteriol (2003) 1.04
Strong cross-system interactions drive the activation of the QseB response regulator in the absence of its cognate sensor. Proc Natl Acad Sci U S A (2013) 1.03
Transposon mutagenesis identifies uropathogenic Escherichia coli biofilm factors. J Bacteriol (2012) 1.02
Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice. Antimicrob Agents Chemother (2012) 1.02
Positively selected FimH residues enhance virulence during urinary tract infection by altering FimH conformation. Proc Natl Acad Sci U S A (2013) 1.02
Disruption of male sexual behavior in rats by tetrahydrofurandiols (THF-diols). Steroids (2005) 1.00
C-Terminal properties are important for ring-fused 2-pyridones that interfere with the chaperone function in uropathogenic E. coli. Org Biomol Chem (2005) 0.98
Design, synthesis and evaluation of peptidomimetics based on substituted bicyclic 2-pyridones-targeting virulence of uropathogenic E. coli. Bioorg Med Chem (2006) 0.96
The differential affinity of the usher for chaperone-subunit complexes is required for assembly of complete pili. Mol Microbiol (2010) 0.95
Ubiquitin is a novel substrate for human insulin-degrading enzyme. J Mol Biol (2010) 0.94
Mapping pilicide anti-virulence effect in Escherichia coli, a comprehensive structure-activity study. Bioorg Med Chem (2012) 0.94
The E. coli CsgB nucleator of curli assembles to β-sheet oligomers that alter the CsgA fibrillization mechanism. Proc Natl Acad Sci U S A (2012) 0.94
Conformational states and recognition of amyloidogenic peptides of human insulin-degrading enzyme. Proc Natl Acad Sci U S A (2013) 0.94
Design and parallel solid-phase synthesis of ring-fused 2-pyridinones that target pilus biogenesis in pathogenic bacteria. J Comb Chem (2002) 0.93
Stromal cells participate in the murine esophageal mucosal injury response. Am J Physiol Gastrointest Liver Physiol (2013) 0.92
Domain activities of PapC usher reveal the mechanism of action of an Escherichia coli molecular machine. Proc Natl Acad Sci U S A (2012) 0.90
Pilin and sortase residues critical for endocarditis- and biofilm-associated pilus biogenesis in Enterococcus faecalis. J Bacteriol (2013) 0.90
Design and synthesis of fluorescent pilicides and curlicides: bioactive tools to study bacterial virulence mechanisms. Chemistry (2012) 0.89
Synthetic polymer nanoparticles conjugated with FimH(A) from E. coli pili to emulate the bacterial mode of epithelial internalization. J Am Chem Soc (2012) 0.89
Human esophageal myofibroblasts secrete proinflammatory cytokines in response to acid and Toll-like receptor 4 ligands. Am J Physiol Gastrointest Liver Physiol (2015) 0.88
Structural basis of Streptococcus pyogenes immunity to its NAD+ glycohydrolase toxin. Structure (2011) 0.88
Carboxylic acid isosteres improve the activity of ring-fused 2-pyridones that inhibit pilus biogenesis in E. coli. Bioorg Med Chem Lett (2008) 0.87
Molecular basis of usher pore gating in Escherichia coli pilus biogenesis. Proc Natl Acad Sci U S A (2013) 0.86
Multivariate design, synthesis, and biological evaluation of peptide inhibitors of FimC/FimH protein-protein interactions in uropathogenic Escherichia coli. J Med Chem (2005) 0.84
NMR studies of interactions between periplasmic chaperones from uropathogenic E. coli and pilicides that interfere with chaperone function and pilus assembly. Org Biomol Chem (2005) 0.84
Impairment of the biomechanical compliance of P pili: a novel means of inhibiting uropathogenic bacterial infections? Eur Biophys J (2012) 0.83
Tetrahydrofurandiol stimulation of phospholipase A2, lipoxygenase, and cyclooxygenase gene expression and MCF-7 human breast cancer cell proliferation. Environ Health Perspect (2007) 0.82
The structure of the PapD-PapGII pilin complex reveals an open and flexible P5 pocket. J Bacteriol (2012) 0.82
Identification of nuclear type II [(3)H]estradiol binding sites as histone H4. Biochem Biophys Res Commun (2002) 0.81
Structure-activity relationships of galabioside derivatives as inhibitors of E. coli and S. suis adhesins: nanomolar inhibitors of S. suis adhesins. Org Biomol Chem (2005) 0.81
Quaternary structure of a SPATE autotransporter protein. Mol Membr Biol (2006) 0.81
Synthesis and application of a bromomethyl substituted scaffold to be used for efficient optimization of anti-virulence activity. Eur J Med Chem (2011) 0.81
Reconstitution of the type II [3H]estradiol binding site with recombinant histone H4. J Steroid Biochem Mol Biol (2006) 0.79
Syntheses and biological evaluation of 2-amino-3-acyl-tetrahydrobenzothiophene derivatives; antibacterial agents with antivirulence activity. Org Biomol Chem (2014) 0.78
Antitoxins: therapy for stressed bacteria. Nat Chem Biol (2011) 0.76
Regulation of the nitric oxide pathway genes by tetrahydrofurandiols: microarray analysis of MCF-7 human breast cancer cells. Cancer Lett (2008) 0.76
Stereoselective synthesis of optically active bicyclic beta-lactam carboxylic acids that target pilus biogenesis in pathogenic bacteria. Org Biomol Chem (2003) 0.75
Trisomy 6 acquired in lymphoid blast transformation of chronic myelocytic leukemia with t(9;22). Cancer Genet Cytogenet (2003) 0.75